ClinicalTrials.gg
TerminatedNCT01268618Updated Jul 21, 2011

Trenev Trio/Healthy Trinity for Symptoms of Diarrhea-predominant Irritable Bowel Syndrome (IBS) and Functional Dyspepsia

A Phase 2/3 interventional study of Probiotic and Placebo in IBS-D and Functional Dyspepsia, sponsored by Sprim Advanced Life Sciences. Terminated at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-07-21.

Sponsored by Sprim Advanced Life Sciences · Phase 2/3, Interventional, and Treatment

Phase
Phase 2/3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Primary Objective:

  • To confirm the efficacy of the probiotic product Healthy Trinity (retail label)/Trenev Trio (professional label) in the improvement of symptoms in adult patients with diarrhea-predominant irritable bowel syndrome (IBS-D) and functional dyspepsia

Secondary Objective:

  • To confirm the safety of the probiotic product Healthy Trinity (retail label)/Trenev Trio (professional label) in adult patients with IBS-D and functional dyspepsia
02

Conditions studied

  • IBS-D and Functional Dyspepsia

Browse trials for

Keywords

  • IBS
  • Diarrhea
  • Dyspepsia
03

In context

Diarrhea

877 studies on the registry are indexed under Diarrhea; 76 are open to participants now.

This study's planned enrollment of 120 is below the median of 137 across 738 interventional studies indexed under Diarrhea.

Browse Diarrhea studies →

Lead sponsor

Sprim Advanced Life Sciences is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 to 75 years
  2. Diagnosed with IBS-D including: a) weekly average of worst abdominal pain in the last 24 hours of ≥3 on a 0-10 scale, and b) weekly average of Bristol Stool form of ≥6 on a 1-7 scale
  3. Diagnosed with functional dyspepsia defined as presence of at least one of the following symptoms: bothersome postprandial fullness, early satiation, epigastric pain, or epigastric burning AND no evidence of structural disease that is likely to explain the symptoms
  4. History of IBS-D and dyspepsia symptoms for at least 12 weeks
  5. Agree to use throughout study period, unless or surgically sterile (females only)
  6. Able to understand the nature and purpose of the study including potential risks and side effects
  7. Willing to consent to study participation and to comply with study requirements
  8. Successful completion of 2-week placebo-only run-in period, defined as ≥90% product compliance and completion of required questionnaires

Exclusion criteria

Exclusion Criteria:

  1. Major gastrointestinal complication, e.g. Crohn's disease or ulcer
  2. Prior abdominal surgery with the exception of hernia repair and appendectomy
  3. Subjects over 60 years who have not had a sigmoidoscopy or colonoscopy in the past 10 years
  4. systemic disease
  5. \< 6 months
  6. Pregnant female or breastfeeding
  7. Lactose intolerance
  8. Immunodeficient subjects
  9. Anti-psychotic medication within the prior 3 months or major psychiatric disorder within the past 2 years
  10. Systemic within the prior month
  11. Current treatment with nasogastric tube, ostomy, or parenteral nutrition
  12. Use of proton pump inhibitors
  13. Eating disorder
  14. Recent (\< 2 weeks) antibiotic administration
  15. History of alcohol, drug, or medication abuse
  16. Daily consumption of probiotics, fermented milk, and/or yogurt
  17. Known allergies to any substance in the study product
  18. Participation in another study with any product within 3 months of screening
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Probiotic

    Dietary Supplement: Probiotic

  • Placebo comparator
    Placebo

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementProbiotic

    2 capsules, 3x/day capsules of Healthy Trinity (retail label)/Trenev Trio (professional label), for a total daily dose of: 1. Lactobacillus acidophilus NAS, 30 billion CFU 2. Bifidobacterium bifidum Malyoth, 120 billion CFU 3. Lactobacillus delbrueckii subspecies bulgaricus LB-51, 30 billion CFU

  • Dietary supplementPlacebo

    2 capsules, 3x/day placebo capsules

06

What researchers measure

Primary outcomes

  1. Abdominal pain severity

    Time frame: 8 weeks

  2. Stool consistency (Bristol Stool Chart)

    Time frame: 8 weeks

  3. Dyspepsia Symptom Severity Index (DSSI)

    Time frame: 8 weeks

Secondary outcomes

  1. Proportion of subjects with 1 or more adverse events

    Time frame: 8 weeks

07

Study locations

2 sites
  • In-Quest Medical Research, LLC
    Duluth, Georgia 30096, United States
  • Clinical Research Associates of Tidewater
    Norfolk, Virginia 23507, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2010
First posted
Dec 31, 2010
Start
Jan 2011
Primary completionEst.
Aug 2011
CompletionEst.
Aug 2011
Last update
Jul 21, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01268618
Lead sponsor
Sprim Advanced Life Sciences
First posted
Dec 31, 2010
Start date
Jan 2011
Primary completion
Aug 2011 (estimated)
Completion
Aug 2011 (estimated)
Last update
Jul 21, 2011

Study contacts

Duane Wombolt, MD
principal investigator · Clinical Research Associates of Tidewater
David Wyatt, MD
principal investigator · In-Quest Medical Research, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Probiotic

Start the discussion